本文關(guān)鍵詞：Linker長(zhǎng)度對(duì)MDC和CVB3VP1融合基因疫苗免疫效果的影響　出處：《河北醫(yī)科大學(xué)》2007年碩士論文　論文類(lèi)型：學(xué)位論文

  更多相關(guān)文章： 巨噬細(xì)胞源趨化因子(MDC) 柯薩奇病毒B組3型(CVB3) Linker 核酸疫苗 中和抗體 小鼠

【摘要】： 目的:柯薩奇病毒B組3型(Coxsackievirus group B type 3, CVB3)是導(dǎo)致人類(lèi)急、慢性心肌病的重要病原一。其預(yù)防和治療性疫苗的研究極為迫切。VP1是CVB3主要的衣殼蛋白,含有多個(gè)T、B細(xì)胞表位,可誘導(dǎo)機(jī)體產(chǎn)生免疫應(yīng)答。國(guó)內(nèi)外研究表明,編碼VP1的DNA疫苗,能誘導(dǎo)小鼠產(chǎn)生體液和細(xì)胞免疫應(yīng)答,并對(duì)感染小鼠具有一定的保護(hù)能力,但不能有效阻止致死量病毒感染。研究證明,一些細(xì)胞因子作為基因佐劑,可大大提高DNA疫苗的免疫效應(yīng)。本室構(gòu)建了MDC ( macrophage-derived chemokine, MDC )與CVB3VP1融合基因質(zhì)粒,保護(hù)率有一定的提高,但不能達(dá)到實(shí)用程度。推測(cè)可能是融合蛋白中某一成分或兩種成分發(fā)生空間結(jié)構(gòu)的不利變化,影響與APCs結(jié)合和/或VP1蛋白的免疫原性。如何保證融合蛋白的穩(wěn)定性和生物學(xué)活性是本研究探討的問(wèn)題。 接頭序列(Linker)的介入是基因融合技術(shù)之一,即通過(guò)一段適當(dāng)?shù)暮塑账嵝蛄袑⒉煌哪康幕蜻B接起來(lái),使之在適當(dāng)?shù)纳矬w內(nèi)表達(dá)成為一條單一的肽鏈,其中起連接作用的氨基酸稱(chēng)為L(zhǎng)inker。Linker的選擇對(duì)構(gòu)建有功能活性的融合蛋白是至關(guān)重要的。它的存在有利于蛋白質(zhì)兩側(cè)功能區(qū)的正確折疊,以允許形成各自獨(dú)立的構(gòu)象。長(zhǎng)度和組成是選擇Linker時(shí)主要應(yīng)考慮的問(wèn)題。研究表明,親水性強(qiáng)和柔性好的Linker是構(gòu)建融合蛋白的首選。故甘氨酸(glycine, Gly, G)和絲氨酸(serine, Ser, S)是構(gòu)建Linker的常用氨基酸。G是所有氨基酸中分子量最小,沒(méi)有手性碳,所以柔性最好,S是親水性最強(qiáng)的氨基酸,能增加親水性。Linker的長(zhǎng)度過(guò)長(zhǎng),在融合蛋白的生產(chǎn)過(guò)程中對(duì)蛋白酶比較敏感,導(dǎo)致活性融合蛋白的產(chǎn)量減低,應(yīng)用較短的Linker,可以克服重組蛋白酶分解的問(wèn)題,但可能使兩個(gè)分子距離太近導(dǎo)致蛋白功能的喪失。據(jù)資料顯示10-22個(gè)氨基酸效果較好。故本研究引入長(zhǎng)度為10、15、19個(gè)由G和S組成的Linker來(lái)構(gòu)建表達(dá)MDC與CVB3VP1融合蛋白核酸疫苗。 方法:(1)用PCR方法分別擴(kuò)增出帶Linker的MDC-L15(用于構(gòu)建Linker長(zhǎng)度為15個(gè)氨基酸的融合蛋白)、MDC-L19(用于構(gòu)建Linker長(zhǎng)度為19個(gè)氨基酸的融合蛋白)、L15-VP1(用于構(gòu)建Linker長(zhǎng)度為15個(gè)氨基酸的融合蛋白)和L19-VP1(用于構(gòu)建Linker長(zhǎng)度為19個(gè)氨基酸的融合蛋白)片段;(2)將4種基因的擴(kuò)增產(chǎn)物與pGEM-T載體連接,轉(zhuǎn)化DH5α大腸桿菌,接種含Amp的2YT培養(yǎng)基,提取質(zhì)粒進(jìn)行酶切鑒定和測(cè)序篩選重組子;(3)經(jīng)酶切鑒定和測(cè)序確認(rèn)后,用合適的核酸內(nèi)切酶從這4種克隆載體切取目的基因片段。將目的基因片段MDC-L15和L15-VP1與經(jīng)合適限制性?xún)?nèi)切酶酶切的pcDNA3載體連接,構(gòu)建真核表達(dá)重組質(zhì)粒pcDNA3/MDC-L15-VP1。同樣的方法構(gòu)建pcDNA3/ MDC-L19-VP1。(4)用堿裂解法從轉(zhuǎn)化的DH5α大腸桿菌中大量提取質(zhì)粒pcDNA3/MDC-L19-VP1、pcDNA3/MDC- L15- VP1、pcDNA3/MDC-L10-VP1、pcDNA3/VP1和pcDNA3,用聚乙二醇(PEG)沉淀法進(jìn)行純化;(5)動(dòng)物實(shí)驗(yàn):將6周齡雄性BALB/c小鼠隨機(jī)分為5組,每組14只;5組分別為pcDNA3組、pcDNA3/VP1組、pcDNA3/MDC-L10-VP1組、pcDNA3/MDC-L15-VP1組和pcDNA3/MDC-L19-VP1組。純化后的質(zhì)粒以生理鹽水稀釋后,股四頭肌注射免疫小鼠,每次每只接種100μg,每4周免疫1次,共免疫3次;于2、6、10周,眼眶靜脈取血,分離血清,用微量中和試驗(yàn)(固定病毒-稀釋血清法)檢測(cè)血清中CVB3特異性中和抗體。第3次免疫后3周,每組3只小鼠取脾臟用于檢測(cè)細(xì)胞免疫水平,每組8只小鼠用5 LD50的CVB3腹腔內(nèi)攻擊,觀察并記錄小鼠死亡情況至感染后第21天。每組剩余的3只小鼠用3 LD50CVB3攻擊,注射病毒后第7天取血,分離血清進(jìn)行病毒滴度測(cè)定。處死后,取心臟,制備石蠟切片,HE染色,觀察各組小鼠心肌病理學(xué)改變。 結(jié)果:(1) PCR擴(kuò)增出MDC-L15、MDC-L19、L15-VP1和L19-VP1基因片段,基因片段的長(zhǎng)度與預(yù)期值相符。(2)成功構(gòu)建了原核克隆載體pGEM-T/MDC-L15,pGEM-T /MDC-L19, pGEM-T/L15-VP1和pGEM-T/L19 -VP1, DNA測(cè)序證實(shí)目的基因序列與Genbank登錄序列相同。(3)基因片段插入pcDNA3后酶切結(jié)果證實(shí)成功構(gòu)建了pcDNA3/MDC-L15-VP1和pcDNA3/MDC-L-19-VP1。(4)不同免疫次數(shù),各組血清中和抗體的平均效價(jià)分別為:pcDNA3/VP1組1:7.07,1:10.59,1:25.20;pcDNA3/MDC- L10-VP1組1:7.93,1:22.45,1:31.74; pcDNA3/MDC-L15-V P1組1:8.91,1:23.78,1:39.99;pcDNA3/MDC-L9-VP1組1:10.00,1:25.20,1:50.39;pcDNA3組各次平均效價(jià)均低于1:5。pcDNA3/VP1、pcDNA3/MDC-L10-VP1、pcDNA3/MDC-L15-VP1和pcDNA3/MDC-L19-VP1組中和抗體滴度隨免疫次數(shù)增加而提高,經(jīng)單因素方差分析差別有統(tǒng)計(jì)學(xué)意義(P0.01);第三次免疫后,除pcDNA3/VP1組和pcDNA3/MDC-L10-VP1組無(wú)顯著性差異,其余各組兩兩比較均有顯著性差異(P 0.01)。(5)特異性淋巴細(xì)胞增殖實(shí)驗(yàn)和CTL殺傷實(shí)驗(yàn)結(jié)果表明,隨Linker長(zhǎng)度的增加增殖能力和殺傷活性顯著增強(qiáng),pcDNA3/MDC-L19-VP1組和其它各組相比差別均有統(tǒng)計(jì)學(xué)意義(P0.01)。(6)用5LD50攻擊小鼠,各組21天生存率分別為:pcDNA3/MDC-L-15-VP1組和pcDNA3/MDC-L19-VP1組均為37.5%,pcDNA3/MDC-L10- VP1組25.0%,pcDNA3/VP1組12.5%, pcDNA3組11天內(nèi)全部死亡。(7)隨Linker長(zhǎng)度的增加血中病毒滴度依次降低, pcDNA3/MDC-L19-VP1組小鼠和其它各組相比差別均有統(tǒng)計(jì)學(xué)意義。(8)心肌病理學(xué)檢查隨Linker長(zhǎng)度的增加心肌病理改變依次減輕,但并無(wú)明顯異。 結(jié)論:(1)用PCR方法成功擴(kuò)增MDC-L15、MDC-L19、L15-VP1和L19-VP1基因片段。(2)成功構(gòu)建真核表達(dá)質(zhì)粒pcDNA3/MDC-L15-VP1、pcDNA3/MDC-L19-VP1。(3)用5LD50的CVB3攻擊后,小鼠的生存率隨著Linker長(zhǎng)度的加長(zhǎng)有一定的提高。(4)小鼠血清中和抗體滴度隨免疫次數(shù)的增加而提高,第三次免疫后pcDNA3/MDC-L19-VP1組中和抗體滴度最高,與其它各組相比差異均有統(tǒng)計(jì)學(xué)意義。(5)特異性淋巴細(xì)胞增殖實(shí)驗(yàn)和CTL殺傷實(shí)驗(yàn)結(jié)果表明pcDNA3/MDC-L19-VP1組增殖指數(shù)和殺傷率最高,與其它各組相比差異均有統(tǒng)計(jì)學(xué)意義。(6)中和抗體滴度、細(xì)胞免疫檢測(cè)、血中病毒滴度、和心肌切片病理學(xué)分析結(jié)果一致,說(shuō)明融合基因疫苗pcDNA3/MDC-L19-VP1是較理想的一種疫苗。
[Abstract]:Objective: coxsackievirus B 3 (Coxsackievirus group B type 3, CVB3) is an important pathogen causing human acute and chronic cardiomyopathy. The prevention and treatment of AIDS vaccine research is extremely urgent.VP1 is a major capsid protein of CVB3 contains a number of T, B cell epitope can induce immune response. The domestic and foreign research shows that VP1 encoding DNA vaccine can induce the humoral and cellular immune responses induced by mice, and has a protective ability of infected mice, but can not effectively prevent lethal virus infection. Studies have shown that some cytokines as an adjuvant, can greatly improve the immune effect of DNA vaccine. The room construction MDC (macrophage-derived chemokine MDC) and CVB3VP1 fusion gene plasmid, the protection rate increased to a certain extent, but can not reach the practical level. That is a component of a fusion protein or two components of space The unfavorable changes of structure affect the immunogenicity of APCs binding and / or VP1 protein. How to ensure the stability and biological activity of fusion protein is the problem discussed in this study.
Joint sequence (Linker) is one of the intervention of gene fusion technology, through an appropriate nucleotide sequence linking different target gene, making it a single peptide expressed in appropriate organisms, including the amino acid called Linker.Linker to construct a functional activity of the fusion protein was essential. It is conducive to the correct folding of protein function area on both sides, to allow the formation of conformation independent. The length and composition is mainly the choice of Linker should be considered. The results show that strong hydrophilicity and flexibility of Linker is to construct the fusion protein. The preferred glycine (Glycine, Gly, G) serine (serine, Ser, and S) is a common amino acid.G to construct the Linker molecules of all amino acids in the minimum amount, no chiral carbon, so the best S is the most flexible, hydrophilic amino acid, can To increase the hydrophilicity of.Linker length is too long, in the production process of fusion protein of protease sensitive activity in the fusion protein yield decreased by short Linker, can overcome the recombinant protease decomposition problem, but may make two molecules too close to lead to the loss of protein function. According to the data shows good 10-22 amino acids the purpose of this study is introduced. The effect of length 10,15,19 is composed of G and S Linker to construct the MDC expression of CVB3VP1 fusion protein and nucleic acid vaccine.
Methods: (1) were amplified by PCR with Linker MDC-L15 (Linker for the construction of a length of 15 amino acid fusion protein (MDC-L19), Linker is used to build the length of 19 amino acid fusion protein (L15-VP1), Linker is used to build the length of 15 amino acid fusion protein (L19-VP1) and used to construct Linker the length of 19 amino acid fragment fusion protein); (2) the amplified products were connected with pGEM-T vector 4 genes, transformation of Escherichia coli DH5 alpha, inoculation with Amp 2YT medium, extraction of plasmid enzyme digestion and sequencing screening recombinant; (3) confirmed by enzyme digestion and sequencing after that cut the target gene fragment from the 4 kinds of cloning vector by endonuclease appropriate. The target gene fragments of MDC-L15 and L15-VP1 and the suitable vector pcDNA3 restriction endonuclease connection, construct eukaryotic expression recombinant plasmid pcDNA3/MDC-L15-VP1. the same way Construction of pcDNA3/ MDC-L19-VP1. (4) extracting plasmid pcDNA3/MDC-L19-VP1 from Escherichia coli DH5 alpha conversion by alkaline lysis method, pcDNA3/MDC- L15- VP1, pcDNA3/MDC-L10-VP1, pcDNA3/VP1 and pcDNA3, using polyethylene glycol (PEG) was purified by precipitation method; (5) animal experiment: 6 week old male BALB/c mice were randomly divided into 5 groups, each group 14; 5 groups were divided into pcDNA3 group, pcDNA3/VP1 group, pcDNA3/MDC-L10-VP1 group, pcDNA3/MDC-L15-VP1 group and pcDNA3/MDC-L19-VP1 group. The purified plasmid was diluted with saline after femoral head four muscle injection of immune mice, each with 100 g, 1 times of immunization every 4 weeks, a total of 3 times of immunization in 2,6,10 weeks,; orbital venous blood, serum separation, micro neutralization test (fixed virus serum dilution method) to detect serum CVB3 specific neutralizing antibodies. Third 3 weeks after immunization, 3 mice in each group were used to detect the cellular immunity of the spleen, n = 8 Mice with 5 LD50 CVB3 intraperitoneal attack, observe and record the death of mice to twenty-first days after infection. 3 mice in each group with the remaining 3 LD50CVB3 attack, blood samples were collected seventh days after infected, the virus titer of the serum were separated from heart. After the execution, and the preparation of paraffin section, HE staining, observation study the pathological changes of myocardium in mice.
Results: (1) PCR amplified MDC-L15, MDC-L19, L15-VP1 and L19-VP1 gene fragments, and the expected length gene fragment valuescorrespond. (2) successfully constructed prokaryotic cloning vector pGEM-T/MDC-L15, pGEM-T /MDC-L19, pGEM-T/L15-VP1 pGEM-T/L19 and -VP1 DNA sequencing confirmed that the gene sequence and the Genbank sequence of the same log. (3) gene fragment insert pcDNA3 after enzyme digestion confirmed the successful construction of pcDNA3/MDC-L15-VP1 and pcDNA3/MDC-L-19-VP1. (4) different immune times, the average titer of neutralizing antibody in serum were respectively: group pcDNA3/VP1 1:7.07,1: 10.59,1:25.20; pcDNA3/MDC- L10-VP1 1:7.93,1:22.45,1:31.74 pcDNA3/MDC-L15-V P1 group; 1:8.91,1:23.78,1:39.99 group; pcDNA3/MDC-L9-VP1 1:10.00,1:25.20,1:50.39 group; pcDNA3 group the average titer were lower than those of 1:5.pcDNA3/VP1, pcDNA3/MDC-L10-VP1, pcDNA3/MDC-L15-VP1 and pcDNA3/MDC-L19-VP1 the titer of neutralizing antibody group To increase the number of immune, the single factor analysis of variance the difference was statistically significant (P0.01); after the third immunization, except pcDNA3/VP1 group and pcDNA3/MDC-L10-VP1 group had no significant difference between the 22 groups, there were significant differences (P 0.01). (5) the specific lymphocyte proliferation assay and CTL cytotoxicity assay results show that with the increase of Linker length proliferation and killing activity was significantly enhanced, compared the difference of both pcDNA3/MDC-L19-VP1 group and other groups (P0.01). (6) the mice were challenged with 5LD50, the survival rate of 21 groups respectively: pcDNA3/MDC-L-15-VP1 group and pcDNA3/MDC-L19-VP1 group were 37.5%, pcDNA3/MDC-L10- and 25% in VP1 group, pcDNA3/VP1 group of 12.5%. The pcDNA3 group all died within 11 days. (7) with the increase of Linker length in order to reduce the virus titer in the blood group pcDNA3/MDC-L19-VP1, mice and other groups showed statistical differences. (8) myocardial pathology examination decreased in turn with the increase of Linker length, but there was no significant difference.
Conclusion: (1) were successfully amplified by PCR MDC-L15, MDC-L19, L15-VP1 and L19-VP1 gene fragments. (2) the eukaryotic expression plasmid pcDNA3/MDC-L15-VP1 was successfully constructed, pcDNA3/MDC-L19-VP1. (3) by 5LD50 CVB3 after the attack, the survival rate of mice with Linker length extension has improved to some extent. (4) serum neutralizing antibody titer with the times of immunization increased, after the third immunization group pcDNA3/MDC-L19-VP1 neutralizing antibody titers, compared with that of the other groups were statistically significant. (5) the specific lymphocyte proliferation assay and CTL cytotoxicity test results showed that the proliferation index in pcDNA3/MDC-L19-VP1 group and the killing rate was the highest compared with other groups, the differences were statistically significant (6). The titer of neutralizing antibody, immune detection, virus titer in the blood and myocardial pathological section analysis showed that this fusion gene vaccine pcDNA3/MDC-L19-VP1 is ideal A vaccine.

【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2007
【分類(lèi)號(hào)】：R392

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 江山,朱道銀,蔣英,駱旭東,陳全;結(jié)核分枝桿菌Ag85B-Ag85A雙抗原融合真核表達(dá)質(zhì)粒的構(gòu)建及表達(dá)[J];第四軍醫(yī)大學(xué)學(xué)報(bào);2003年21期

2 劉暢;孫林英;劉秀麗;邵曉婷;譚曉華;劉端祺;;mGM-CSF-mMIP-3α重組質(zhì)粒的構(gòu)建、表達(dá)及鑒定[J];華北國(guó)防醫(yī)藥;2006年01期

3 倪志宇,王永祥,金玉懷,金世香;柯薩奇病毒B組3型VP1基因真核表達(dá)重組質(zhì)粒的構(gòu)建及免疫效果[J];河北醫(yī)科大學(xué)學(xué)報(bào);2002年03期

4 楊登科;靳風(fēng)爍;張勇;;Ag85B/IL-2融合蛋白在體外對(duì)PBMC增殖及Th1型細(xì)胞因子分泌的影響[J];醫(yī)學(xué)臨床研究;2006年02期

5 王曉凌;高志云;耿媛;金玉懷;王永祥;;融合基因DNA疫苗pcDNA3/MDC-VP1對(duì)柯薩奇病毒B組3型的免疫效果[J];臨床心血管病雜志;2006年07期

6 朱莉,王靈樞,劉晶星,陸德源,袁正宏,聞?dòng)衩?柯薩奇B組病毒3型VPI基因疫苗免疫效果的研究[J];上海第二醫(yī)科大學(xué)學(xué)報(bào);1999年03期

7 張愛(ài)華,彭夫望,閉蘭,張智,王志友,史良如;抗轉(zhuǎn)鐵蛋白受體鼠源性單鏈抗體基因的構(gòu)建、表達(dá)及初步鑒定[J];中國(guó)生物制品學(xué)雜志;2005年02期

8 吳志洪,黃漢菊,秦國(guó)偉,潘俠;漢坦病毒H8205株G2-人源IL-2融合基因免疫效果的研究[J];華中科技大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2005年01期

9 徐薇,沈燕,王立新,許從峰,鄭秀娟,熊思東;CVB3-VP1基因免疫誘導(dǎo)特異性抗病毒免疫應(yīng)答及保護(hù)作用[J];細(xì)胞與分子免疫學(xué)雜志;2003年03期

10 李暉;李榕;鐘森;羅月貝;任紅;鄧存良;;Mtb8.4/hIL12嵌合基因疫苗免疫原性[J];細(xì)胞與分子免疫學(xué)雜志;2006年05期

，

本文編號(hào)：1381484